Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.
In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol. The Metoclopramide-induced secretion of prolactin and aldosterone was blunted in 6 patients pretreated with 200 mg ibopamine. The data are consistent with a dopaminergic effect of ibopamine due to a peripheral action, probably on D-2 receptors.
D000328:Adult; D000450:Aldosterone / Q000378:metabolism*; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000378:metabolism*; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D000450:Aldosterone; C023487:ibopamine; D011388:Prolactin; D013006:Growth Hormone; D003846:Deoxyepinephrine; D004298:Dopamine; D006854:Hydrocortisone